American College of Cardiology (ACC)

LBCT (410-10): Benefit Of Dapagliflozin On First And Repeat Events In Patients With HFrEF In DAPA-HF [TIME STAMP 15:29]

Oral Presentation (902-06): Consistent Benefit of Dapagliflozin According to Background Therapy in Patients with HFrEF: An Analysis of The DAPA-HF Trial

Moderated Poster (1027-07): Dapagliflozin improves outcomes Irrespective of NT-ProBNP Concentration in Patients with HFrEF: An Analysis of The DAPA-HF Trial

Moderated Poster (1027-03):Effect of Treatment with Dapagliflozin is Consistent Across the Range of Body Mass Index in Patients with HFrEF: An Analysis of The DAPA-HF Trial

Moderated Poster (1003-03): Effects of dapagliflozin on cardiovascular outcomes across BMI categories in patients with type 2 diabetes mellitus in the DECLARE TIMI-58 Trial

Poster (1112-210): Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in type 2 diabetes patients: a randomized placebo-controlled study

Poster (1259-069): Effect of Treatment with Dapagliflozin According to Baseline Systolic Blood Pressure in Patients with HFrEF: An Analysis of The DAPA-HF Trial

Poster (1260-152): Heart Failure Hospitalizations And Urgent Heart Failure Visits For Patients With Heart Failure In A Real-World Population In the US

LBCT (410-10): Safety And Efficacy Of Ticagrelor Monotherapy After Complex PCI: The TWILIGHT-COMPLEX Substudy [TIME STAMP 16:18]

LBCT (410-16): Ticagrelor With And Without Aspirin In High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From The TWILIGHT Trial [TIME STAMP 1:05:42]

LBCT (independent study) (410-08) Ticagrelor w or w/o Aspirin In ACS After PCI: Randomized Eval Of Ticagrelor Monotherapy After 3-month Dual-antiplatelet Therapy In ACS {TIME STAMP 01:42}

Poster (1211-190): Antithrombotic Therapy In Atrial Fibrillation Subjects After Percutaneous Coronary Intervention With Drug-eluting Stent

Oral Presentation (906-04): Performance of a Novel Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease

Oral Presentation (906-08): Polyvascular disease with and without diabetes and the risk of adverse cardiovascular and limb events in the EUCLID trial

Poster (1268-205): Ticagrelor and Major Adverse Limb Events: A Systematic Review and Meta-Analysis

Poster (1363-171): Multi-morbidity, functional impairment and mortality in older patients after acute myocardial infarction: a report from the Tigris registry

Poster (1412-029): Platelet and Monocyte Activation After Transcatheter Aortic Valve Replacement (POTENT-TAVR): Randomized Controlled Trial of Ticagrelor versus Clopidogrel